is the tirzepatide shortage over Eli Lilly joins FDA as Defendant in Lawsuit FDA Says Shortage of GLP-1

Jastreboff AM, Aronne LJ, Ahmad NN et al

The SURPASS clinical trial programme, which evaluated tirzepatide's safety and efficacy across thousands of participants, did not identify peripheral neuropathy or paraesthesia as a significant adverse event attributable to the medication, as summarised in the European Medicines Agency's European Public Assessment Report (EPAR)

Managing Constipation: If constipation has been an issue, it may persist, but by now, you should have strategies in place, such as increased fluid and fiber intake

Physician supervision is what changes the outcome

This intracellular accumulation of FFAs and their esterified products, such as diacylglycerols and triglycerides, initiates lipotoxicity

Zinc: The literature indicates potential interactions between supplemental zinc and certain antibiotics and diuretics